- 9th Research Conference held at Kosin University Gospel Hospital in Busan; discussion on adopting ‘multi-omics’ for mechanism elucidation. Continued efforts to review globally advanced technologies for data-driven efficacy validation

- NKCL Bio Group proposes integrated immune monitoring system; Molecular You’s Dr. Rob Fraser delivers technical presentation

Kosin University Gospel Hospital (Director Choi Jong-soon), which is preparing clinical trials for NK cell therapy—a next-generation weapon in cancer treatment—is devoting all efforts to scientific mechanism elucidation, including reviewing the adoption of global-level analytical technologies to objectively validate the efficacy of its research.

On the afternoon of the 9th, Kosin University Gospel Hospital held the ‘9th Research Conference’ in Conference Room 1 at the hospital, together with NKCL Bio Group (Chairman Shin Dong-hwa), a biotech company specializing in NK cells, and Molecular You (Rob Fraser, Ph.D/CSO, President & Co-founder), a Canadian AI precision medicine company. This meeting was organized to further develop the academic discussions aimed at enhancing the precision of actual clinical research design, following the 1st online conference held with MYco headquarters executives on January 23.

NKCL Proposes Next-Generation Analytical Model to Kosin University Gospel Hospital

MYco’s Dr. Rob Fraser Steps Forward for ‘Technical Validation’

At this conference, the ‘Integrated Immune Monitoring System’ proposed by NKCL to Kosin University Gospel Hospital was addressed as the core agenda item. NKCL’s academic team proposed a combined model of ‘single-cell RNA analysis (scRNA-seq)’ for identifying the direct mechanisms of cancer cell apoptosis and ‘multi-omics biomarker’ analysis for examining patients’ systemic metabolic responses, thereby establishing the scientific foundation for clinical research.

To conduct professional review and discuss the technical feasibility of this proposal, Dr. Rob Fraser, MYco’s technology developer and Chief Scientific Officer (CSO), personally delivered a presentation. Dr. Fraser provided a detailed introduction of AI-based multi-omics biomarker analysis methods, explaining how NKCL’s proposal could be implemented as high-level data in actual clinical settings.

Data-Driven Immunotherapy: Kosin University Gospel Hospital’s Relentless Research Commitment

Kosin University Gospel Hospital has continuously strived to validate treatment efficacy through ‘objective data’ beyond simple observation in pursuing clinical research utilizing NKCL’s NK cell therapy technology. In particular, the hospital has meticulously explored leading global analytical solutions to build a precision monitoring system covering everything from genetic changes in individual cells to systemic changes throughout the body, and this conference deepened the practical review of these efforts.

Steps Toward Securing Future Bio-Industry Competitiveness

Since signing an MOU in September last year pledging approximately USD 35 million in investment and technology cooperation, NKCL and MYco have been taking phased steps to verify the effectiveness of their collaboration through clinical cooperation with Kosin University Gospel Hospital.

Kosin University Gospel Hospital Director Choi Jong-soon stated, “Our hospital has focused all capabilities on scientific validation so that NK cell therapy can become an innovative treatment opportunity for patients,” adding, “If NKCL’s academic team’s proposal is combined with MYco’s unparalleled analytical technology, we can elevate the credibility of clinical research to a world-class level.”

NKCL Bio Group Chairman Shin Dong-hwa responded, “The combination of advanced manufacturing infrastructure and precise analytical data represents the pinnacle of precision medicine that Korea’s bio-industry must pursue,” adding, “We will spare no effort in providing optimal technical support so that Kosin University Gospel Hospital’s clinical commitment leads to meaningful results.”

MYco completed the establishment of its Korean subsidiary in February and plans to prepare for its official launch in Korea, with this conference as a catalyst. The company also announced that its fundraising is in the final stages.